Literature DB >> 34076862

Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure.

Cristian Bis-Humbert1,2, Rubén García-Cabrerizo1,2,3, M Julia García-Fuster4,5.   

Abstract

BACKGROUND: Further studies are needed to better understand the effects of potential novel antidepressants, such as cannabidiol, for the treatment of psychiatric disorders during adolescence. In this context, we evaluated in a rodent model of early-life stress (a single 24-h episode of maternal deprivation, PND 9), the antidepressant-like effects of adolescent cannabidiol alone and/or in combination with adolescent cocaine exposure (given the described beneficial effects of cannabidiol on reducing cocaine effects).
METHODS: Maternally deprived Sprague-Dawley male rats were treated in adolescence with cannabidiol (with or without concomitant cocaine) and exposed to a battery of behavioral tests (forced-swim, novelty-suppressed feeding, open field, sucrose preference) across time. Putative enduring molecular correlates (CB receptors, BDNF) were evaluated in the hippocampus by western blot.
RESULTS: Cannabidiol exerted antidepressant- and anxiolytic-like effects in rats exposed to early-life stress. Cocaine did not alter affective-like behavior during adolescence in rats exposed to early-life stress; however, a depressive- and anxiogenic-like phenotype emerged during adulthood, and cannabidiol exerted some behavioral improvements, along with the growing literature supporting its beneficial role for reducing cocaine intake and/or reinstatement in rodents. Finally, cannabidiol did not modulate hippocampal CB receptors or BDNF proteins, and although the data raised interesting questions about the possible role of CB1 receptors on modulating the long-term effects of cocaine, future research is needed to expand these findings.
CONCLUSION: Cannabidiol showed a promising therapeutic response in terms of ameliorating affect in a rat model of early-life stress during adolescence and up to adulthood.
© 2021. Maj Institute of Pharmacology Polish Academy of Sciences.

Entities:  

Keywords:  Adolescence; Antidepressant; Cannabidiol; Cocaine; Maternal deprivation; Rat

Mesh:

Substances:

Year:  2021        PMID: 34076862     DOI: 10.1007/s43440-021-00285-5

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  3 in total

1.  Cannabidiol Modulates Behavioural and Gene Expression Alterations Induced by Spontaneous Cocaine Withdrawal.

Authors:  Ani Gasparyan; Francisco Navarrete; Marta Rodríguez-Arias; José Miñarro; Jorge Manzanares
Journal:  Neurotherapeutics       Date:  2020-11-23       Impact factor: 7.620

2.  Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice.

Authors:  Claudia Calpe-López; Ani Gasparyan; Francisco Navarrete; Jorge Manzanares; Jose Miñarro; Maria A Aguilar
Journal:  J Psychopharmacol       Date:  2021-01-09       Impact factor: 4.153

3.  Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial.

Authors:  Violaine Mongeau-Pérusse; Suzanne Brissette; Julie Bruneau; Patricia Conrod; Simon Dubreucq; Guillaume Gazil; Emmanuel Stip; Didier Jutras-Aswad
Journal:  Addiction       Date:  2021-02-09       Impact factor: 6.526

  3 in total
  3 in total

1.  Adolescent cocaine induced persistent negative affect in female rats exposed to early-life stress.

Authors:  Cristian Bis-Humbert; M Julia García-Fuster
Journal:  Psychopharmacology (Berl)       Date:  2021-08-24       Impact factor: 4.415

2.  Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective.

Authors:  Sandra Ledesma-Corvi; Elena Hernández-Hernández; M Julia García-Fuster
Journal:  Transl Psychiatry       Date:  2022-06-01       Impact factor: 7.989

3.  Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats.

Authors:  Elena Hernández-Hernández; M Julia García-Fuster
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.